Angiogenesis, the formation of new blood vessels from pre-existing vasculature, is a
fundamental process during cancer progression. Anti-angiogenic strategies have been …

Drug development is a long process that generally spans about 10 to 15 years. The shift in
recent drug discovery to novel agents against specific molecular targets highlights the need …

We describe extracellular interactions between fibronectin (Fn) and vascular endothelial
growth factor (VEGF) that influence integrin-growth factor receptor crosstalk and cellular …

The development of noninvasive methods to visualize and quantify integrin αvβ3 expression
in vivo appears to be crucial for the success of antiangiogenic therapy based on integrin …

Elevated focal adhesion kinase (FAK) expression occurs in advanced cancers, yet a
signaling role for FAK in tumor progression remains undefined. Here, we suppressed FAK …

Thyroid hormone (l-thyroxine, T (4), or 3, 5, 3'-triiodo-l-thyronine, T (3)) treatment of human
papillary and follicular thyroid cancer cell lines resulted in enhanced cell proliferation …

Class 3 semaphorins (sema 3) are secreted guidance proteins. Sema 3A expressed by
endothelial cells controls vascular morphogenesis through integrin inhibition. Sema 3C is …

Angiogenesis refers to the process of remodeling the vascular tissue characterized by the
branching out of a new blood vessel from a pre‐existing vessel. Angiogenesis is particularly …

Локальное хроническое воспаление повышает риск развития эпителиальных
новообразований. Механизмы такого патогенетического действия хронического …

Activation of the MAPK pathway mediates insulin-like growth factor-I (IGF-I)-dependent
proliferation in vascular smooth muscle cells (SMC). Our previous studies have shown that …